Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX - Free Report) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.
Other research analysts also recently issued reports about the company. Chardan Capital reaffirmed a "buy" rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday, November 20th. Morgan Stanley cut shares of Immuneering from an "equal weight" rating to an "underweight" rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $12.80.
Read Our Latest Stock Analysis on IMRX
Immuneering Price Performance
NASDAQ:IMRX remained flat at $2.36 on Tuesday. 80,774,103 shares of the company's stock were exchanged, compared to its average volume of 20,536,984. The firm has a market capitalization of $73.28 million, a P/E ratio of -1.20 and a beta of -0.34. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The stock's 50 day moving average is $2.03 and its two-hundred day moving average is $1.76.
Institutional Investors Weigh In On Immuneering
Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its position in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after buying an additional 9,400 shares in the last quarter. Corsair Capital Management L.P. bought a new stake in Immuneering during the 3rd quarter valued at about $25,000. Vontobel Holding Ltd. purchased a new stake in Immuneering in the 3rd quarter valued at about $25,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Immuneering in the 2nd quarter worth about $44,000. Institutional investors own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
